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Diagnostic Performance between Contrast Enhancement, Proton MR Spectroscopy and 2 
Amide Proton Transfer Imaging in Patients with Brain Tumors 3 
 4 





To explore the relationship among parameters of magnetic resonance spectroscopy 3 
(MRS) and amide proton transfer (APT) imaging, and to assess the diagnostic 4 
performance of MRS and APT imaging for grading brain tumors in comparison with 5 
contrast enhancement of conventional MRI for preoperative grading in patients with 6 
brain tumor.  7 
Materials and Methods 8 
Institutional review board approval and written informed consent were obtained. 9 
Forty-one patients with suspected brain tumors were enrolled in the study. Single-voxel 10 
MRS and two-dimensional APT imaging of the same slice level were conducted using a 11 
3-T MRI scanner. Positive or negative contrast enhancement on T1-weihted images was 12 
assessed by two neuroradiologists. Correlations among metabolite concentrations, 13 
metabolite ratios, and calculated histogram parameters, including mean APT (APTmean) 14 
and the 90th percentile of APT (APT90) were assessed using Spearman’s correlation 15 
coefficient. Diagnostic performance was evaluated with receiver operating characteristic 16 
(ROC) curve analysis for contrast enhancement, MRS and APT imaging. Values of p < 17 




Positive correlations with statistical significance were found between total concentration 2 
of Cho and APT90 (r=0.49), and between Cho/Cr and APTmean (r=0.65) as well as APT90 3 
(r=0.49). A negative correlation with statistical significance was observed between 4 
NAA/Cr and APTmean (r=-0.52). According to ROC curves, Cho/Cr, APTmean, APT90, 5 
demonstrated higher AUC values than that of contrast enhancement in grading gliomas. 6 
Conclusions 7 
Significant correlations were observed between metabolite concentrations and ratios on 8 
MRS and APT values. MRS and APT imaging showed comparable diagnostic capability 9 
for grading brain tumors, suggesting that both MRS and APT imaging offer potential for 10 
quantitatively assessing similar biological characteristics in brain tumors on 11 
non-contrast MRI. 12 
 13 
 14 
Key Words 15 
Amide proton transfer imaging;  16 
Chemical exchange saturation transfer;  17 
Magnetic Resonance Imaging; 18 
4 
 
Magnetic Resonance Spectroscopy; 1 




Conventional magnetic resonance imaging (MRI) with gadolinium-based 2 
contrast agent has been accepted as a standard method for the characterization of brain 3 
tumors. In particular, disruption of the blood-brain barrier (BBB) as observed on 4 
contrast enhanced (CE) T1-weighted imaging is used as a measure of brain tumor 5 
malignancy and grading. 1 However, the accuracy of this approach is reportedly 6 
limited.2,3 Moreover, with the recent availability of anti-angiogenic pharmacotherapies 7 
such as bevacizumab and other agents,4,5 evaluating the status of brain tumors has been 8 
complicated by the protection of the BBB afforded by these treatment.6 9 
Several studies have investigated the visualization and characterization of brain 10 
tumors without using contrast media. Among these, 1H-magnetic resonance 11 
spectroscopy (MRS) has been established as a technique providing information on 12 
chemical metabolites present in living tissues.7 Amide proton transfer (APT) imaging, a 13 
novel chemical exchange saturation transfer (CEST)-based molecular MRI technique, 14 
has recently been introduced to the clinical setting.8-12 APT imaging is designed to 15 
detect endogenous mobile proteins and peptides in tissues.13 Both MRS and APT 16 
imaging provide metabolic information that can be exploited to study the biological 17 
behaviors of tumors.14,15 18 
6 
 
We assumed that APT imaging and metabolites identified on MRS would show 1 
similarities and correlations and would provide important oncologic information. To 2 
date, several studies have demonstrated that these advanced techniques have the 3 
potential to characterize brain tumors.7-12,16-18 However, very few clinical studies have 4 
discussed correlations between findings from MRS and APT imaging.19  5 
 The objectives of this study were to: 1) explore relationships among parameters 6 
obtained from MRS and APT imaging and 2) assess the diagnostic performance of APT 7 
imaging and MRS for grading brain tumors in comparison with contrast enhancement of 8 
conventional MRI. 9 
 10 
MATERIALS AND METHODS 11 
Patients 12 
The institutional review board of our university approved this study. Written 13 
informed consent was obtained from all patients or their guardian/s. Between May 2013 14 
and August 2014, a total of 41 consecutive patients with suspected brain tumor and 15 
symptoms corresponding to World Health Organization (WHO) performance status ≤2 16 
were enrolled in the study. The following inclusion criteria were used: a) MRS and APT 17 
imaging performed during the same examination; and b) presence of treatment-naïve or 18 
7 
 
recurrent tumor with histological verification. Exclusion criteria were: a) degradation of 1 
image quality due to susceptibility artifacts or motion artifacts; b) unsatisfactory 2 
shimming such as a larger full width at half maximum (FWHM) of water peak reaching 3 
>0.10 ppm; or c) extra-axial tumors such as meningioma. When motion artifacts were 4 
suspected, original series of APT imaging were visually inspected if there are apparent 5 
movements of head position during image acquisition. Five patients were excluded due 6 
to severe motion artifacts during APT imaging (a), 5 patients were excluded due to the 7 
FWHM criterion (b), and 4 patients with lymphoma, one patient with brain metastasis 8 
from melanoma, 5 patients with meningioma were also excluded (c). A final total of 21 9 
patients were thus included in this study.  10 
 11 
MR Imaging 12 
MR Spectroscopy 13 
All MRI was performed using a whole-body 3-T system (Vantage; Toshiba 14 
Medical Systems, Otawara, Japan) with a 32-channel head coil. MRS was obtained 15 
using a single-voxel point-resolved spectroscopic sequence with water suppression 16 
pulse and the following parameters: repetition time (TR), 2000 ms; echo time (TE), 136 17 
ms; flip angle, 90 °; and scan time, 4 min 18 s. The volume of interest (VOI) was placed 18 
8 
 
on the area showing the solid portion of tumor on T2-weighted imaging, and the cystic 1 
or necrotic portion and hemorrhagic regions were carefully avoided. Size of the VOI 2 
varied from 15 × 15 × 15 mm3 to 20 × 20 × 20 mm3, depending on tumor size. 3 
MR data were transferred to a workstation, then MRS was analyzed using 4 
LCModel version 6.3-0C software (LCModel, Ontario, Canada) using the basis set. 5 
Analysis was undertaken on water-suppressed spectral domain data for chemical shifts 6 
in the range of 0.0 - 4.0 ppm. Absolute concentrations of N-acetyl aspartate (NAA), 7 
creatine (Cr) and choline (Cho), and NAA to creatine ratio (NAA/Cr) and choline to 8 
creatine (Cho/Cr) ratios were calculated using known concentrations of tissue water.20 9 
 10 
 11 
APT imaging 12 
APT imaging was conducted with a 2-dimensional fast advanced spin echo 13 
sequence, which is similar to the half-Fourier acquisition single-shot turbo spin-echo 14 
sequence. The imaging slice was set at the midpoint of the VOI of MRS, which enabled 15 
values of APT to be obtained at the VOI of MRS. The following parameters were used 16 
in a single-slice axial acquisition: field of view, 230 × 230 mm; matrix, 256 × 256; TR, 17 
9000 ms; TE, 60 ms; flip angle, 90 °; refocusing flip angle, 160 °; slice thickness, 5mm; 18 
9 
 
bandwidth, 651 Hz/pixel; saturation power, flip angle 500° (1 μT); 1 
magnetization-transfer (MT) Contrast pulse shot, 25; inter-pulse delay, 1 ms; and scan 2 
time, 6 min 9 s. MT spectra over an offset range of ±10 ppm with a step size of 0.5 ppm 3 
with respect to water resonance were obtained.  4 
  5 
Imaging Analysis 6 
Conventional MRI 7 
Two board-certified neuroradiologists (_._. and _._. with 8 and 17 years of 8 
experience) independently analyzed imaging characteristics of brain tumor. They 9 
assessed if contrast enhancement is present (CE +ve) or not (CE -ve) on CE 10 
T1-weighted image of patients with brain tumor. 11 
 12 
APT imaging 13 
The minimum value for MT spectra obtained from APT imaging was estimated 14 
from the original data by spline interpolation with Lorentzian function fitting, and 15 
displacement from the water resonance frequency owing to B0-field inhomogeneity was 16 
corrected. For quantification, asymmetric magnetization transfer ratio (MTRasym) 17 
analysis was performed with respect to the water resonance frequency on the 18 
10 
 
shift-corrected z-spectrum fit between a parameter for amide proton exchange and its 1 
symmetrically opposite side, such that MTRasym(+Δω) = MTR(−Δω) − MTR(+Δω), 2 
where MTR is the magnetization transfer ratio and Δω is the frequency (in parts per 3 
million) of amide and the water exchange site with respect to water (typically between 4 
3.3 and 3.7 ppm) obtained from the shift-corrected z-spectrum. The VOI of MRS was 5 
automatically transferred to the APT image of each patient using an in-house script in 6 
Matlab 2013b (The MathWorks, Natick, MA) (Fig. 1). Finally, mean MTRasym 7 
(APTmean), the 90th percentile of MTRasym (APT90), standard deviation, kurtosis and 8 
skewness of VOIs were calculated.  9 
 10 
Histologic Evaluation 11 
Pathological diagnosis was determined according to WHO 2007 criteria by a 12 
board-certified neuropathologist.21 Grade 1 and 2 were regarded as low grade, while 13 
grade 3 and 4 were regarded as high grade. 14 
 15 
Statistical Analysis 16 
Data were checked by Gaussian distribution and homogeneity testing before 17 
analysis. Intra-rater agreements were assessed with Cohen’s kappa. If there were 18 
11 
 
disagreement between the two raters, third radiologist (_._., a board-certified 1 
neuroradiologist with 24 years of experience) made final decision. Correlations between 2 
parameters obtained from MRS and APT imaging were analyzed using Spearman 3 
correlation analysis. Receiver-operating characteristic (ROC) analyses were conducted 4 
to determine optimal thresholds, as well as sensitivity and specificity for grading brain 5 
tumors with each technique. We used conventional MRI characteristics as reference 6 
standards. Areas under the curve (AUCs) were statistically compared using a method 7 
described by Delong et al.22  8 
All statistical analyses were conducted using Stata version 13 software (Stata 9 




Patient population was summarized in Table 1. Patients comprised 13 males 14 
and 8 females (mean age, 50.0±20.2 years; range, 11–85 years). Tumors comprised 21 15 
gliomas (grade II, n=10; grade III, n=3; grade IV, n=8). Two patients were diagnosed 16 




Intra-rater agreement of conventional MRI analyses by neuroradiologists 1 
CE +ve was diagnosed in 16 patients, and CE -ve was diagnosed in 5 patients 2 
(Table 1). Cohen’s kappa was 1.0 and agreement was 100%. 3 
 4 
Correlations between MRS and APT imaging 5 
Correlations between among metabolites concentration or ratio from MRS and 6 
APTmean or APT90 are summarized in Table 2. Positive correlations with statistical 7 
significance were found between Cho and APT90, and between Cho/Cr and APTmean. 8 
Negative correlations with statistical significance were observed between NAA/Cr and 9 
APTmean. Negative correlations were observed between NAA and APTmean (r=－0.43, 10 
p=0.05). Standard deviation, skewness and kurtosis of APTasym showed no significant 11 
correlations with Cho, NAA Cr, or its ratios (Table. 2). 12 
 13 
Diagnostic capability for grading brain tumors on contrast enhancement, MRS and 14 
APT imaging 15 
ROC curves illustrating the performance of contrast enhancement, Cho, Cho/Cr, 16 
APTmean, APT90 are shown in Fig. 3. According to ROC curves, the APTmean cutoff of 17 
2.72 offered the best combination of sensitivity (72.7%) and specificity (90%) in the 18 
13 
 
characterization of high-grade gliomas, while the APT90 cut-off of 6.61 demonstrated 1 
the optimal combination of sensitivity (90.9%) and specificity (70%).  2 
Total concentration of Cho cutoff of 2.85 provided the best combination of 3 
sensitivity (63.6%) and specificity (100%) among total concentration of metabolites. 4 
Among the ratios of the two metabolites above, the Cho/Cr threshold value of 0.50 5 
generated the best combination of sensitivity (100%) and specificity (93.8%) in the 6 
discrimination of high- and low-grade tumors. AUCs of each parameter were 7 
summarized in Table. 3. All the imaging parameters above except Cho demonstrated 8 
higher AUC values than that of contrast enhancement (AUC was 0.65). None of the 9 
AUCs obtained from these variables showed significant differences (Fig. 3, APT90 vs 10 
APTmean, P=0.74, APT90 vs Cho/Cr, P=0.35, Cho/Cr vs APTmean, P=0.72). 11 
 12 
DISCUSSION 13 
We made two important observations in this study. First, we found significant 14 
moderate correlations between the concentration of metabolites and APTasym parameters. 15 
Few studies have investigated the associations among MRS and CEST. In the literature, 16 
lactate and MTRasym at 3.5 ppm correlated well with infarcted area in induced middle 17 
cerebral artery occlusion,23 and a good correlation was seen between CEST at 2 ppm 18 
14 
 
and creatine concentration for implanted gliosarcoma cells.24 However, those studies 1 
used rat models, and only one clinical study has investigated correlations between MRS 2 
and CEST in human brain tumors.19 Some investigators prefer APT90 or other variables 3 
close to maximum values over mean APT values,8,19 because the 90% histogram cutoff 4 
is less influenced by random statistical fluctuations, and is thus considered superior to 5 
the maximum value.25 When comparing Cho and APT90, a positive correlation was seen 6 
in patients with intra-axial brain tumors, supporting the recent results from Park et al.19 7 
These findings suggest the feasibility of quantitatively assessing similar biological 8 
characteristics in brain tumors using MRS and APT imaging as different modalities. 9 
Such correlation is unlikely to be due to signals from Cho, because the CEST effect at 10 
3.5 ppm from endogenous metabolites including Cho and NAA might not be visible at 11 
3T.26 Generally, malignant tumor cells show high proliferative activity and cellularity. 12 
The Cho peak corresponds to increased cell attenuation and membrane turnover in 13 
neoplastic tissues.27,28 APT values have recently been reported to show moderate 14 
correlations with cell density or MIB-1 index, as a representative marker for 15 
proliferative activity of the brain tumor.9 A possible explanation for the positive 16 
correlation between Cho and APT90, therefore, involves the proliferative activity and 17 
cellularity of tumor cells.  18 
15 
 
We also found a negative correlation between NAA and APTmean. NAA is 1 
predominantly located in neurons and is thus decreased in all neoplasms that cause 2 
neurons to be displaced or replaced with malignant cells.29 Numerous studies have 3 
demonstrated decreased NAA peak, mainly in glial neoplasms30 and primary CNS 4 
lymphoma,31 consistent with our results. Our results also suggest that APTmean indirectly 5 
reflects neuronal loss due to brain tumor infiltration. To testify our hypothesis, further 6 
study including stereotactic biopsy based on the APT image should be needed. 7 
Interestingly, we neither found a positive correlation between Cho and APTmean, 8 
nor between NAA and APT90. A possible explanation for this discrepancy is that APT90 9 
and APTmean may be different biomarkers, and similar discrepancies were reported 10 
between minimum and mean apparent diffusion coefficient from diffusion-weighted 11 
imaging.32 Jiang et al. recently showed that the maximum value from APT imaging was 12 
significantly lower in patients with primary CNS lymphoma than in patients with 13 
Glioblastoma, while APTmean values did not show any such significant differences 14 
between patient groups.12 To clarify and verify different information for these 15 
parameters, further studies are needed. 16 
Second, MRS and APT imaging showed comparable diagnostic performance in 17 
differentiating between high- and low-grade brain tumors. Several studies have shown a 18 
16 
 
significant increase in Cho/Cr in high-grade tumors compared with that of low-grade 1 
tumors at long TE with clinical scanners.17,18 Past studies also demonstrated that the 2 
utility of amount of metabolite or metabolite concentration ratio in grading brain 3 
tumor.33 Recently, APTasym values are reportedly suitable for differentiating between 4 
high- and low-grade brain tumors, mainly in adult populations.8-11 The diagnostic 5 
capability of MRS and APT imaging for grading brain tumors was investigated and 6 
compared with that of conventional MRI in this study. We found that MRS and APT 7 
imaging shows higher AUCs compared with that of grading diagnosed by 8 
neuroradiologists based on conventional MRI. Although conventional MRI including 9 
CE-T1 weighted image has been widely used in pre- and post-operative assessment of 10 
brain tumor, several researchers reported its limited capability of glioma-grading.2,3 Our 11 
result may suggest that these two imaging sequences can give us additional information 12 
of brain tumor even without contrast materials. 13 
Interestingly, metabolite ratios to creatine showed either better correlation with 14 
APT value or diagnostic capability of glioma grading than the concentration. The reason 15 
is hard to explain. Previous study suggested that measuring concentration of metabolites 16 
in brain tumor might be difficult, especially in high-grade glioma.34 Metabolite ratios 17 
are frequently used in MRS studies and assumed as an internal standard, can give us 18 
17 
 
more accurate information in grading glioma than absolute concentration.35 Our results 1 
may be in line with this. 2 
Our study shows several limitations. First, despite several researches including 3 
current study, the origin of APT signal still remains unclear. Many researchers have 4 
demonstrated some biological signature such as cytosolic protein including folding 5 
status or amount of specific protein contributes APT signal.36,37 Furthermore, there are 6 
some discussions about the confounding effects of asymmetry of the solid-phase MT 7 
effect and possible intra- and intermolecular nuclear Overhauser effects (NOE) of 8 
aliphatic protons and T1 value of the tissue to APT-weighted image.38 Some authors 9 
implied or demonstrated that the background MT asymmetry or NOE effects are 10 
negligible on 3T,10 while others argue that MT asymmetry is more significant than APT 11 
effect even on 3T.38 According to the recent researches with ultra-high field MRI, NOE 12 
imaging has potential to delineate portion with high cellularity, or BBB disruption in 13 
glioma without contrast agents.39,40 MT contrast in the brain tumor has been reported to 14 
be decreased compared with white matter, and correlate with nuclear density.41 To 15 
investigate the association among NOE, MT asymmetry and metabolites in brain tumors, 16 
further studies at ultra-high field MRI may be needed. Environmental factors such as 17 
pH and temperature also have great effects on CEST image. pH imaging, which is a 18 
18 
 
cutting-edge application of CEST, and may become a potential marker of hypoxia.42 1 
Recent study showed the promising result of amine-proton based CEST images, which 2 
is focusing on 3 ppm, in detecting intratumoral pH changes.43 However, this effect is 3 
somewhat confusing in the assessment of brain tumor with APT images; High-grade 4 
tumors with high proliferation activity can show acidotic changes due to anaerobic 5 
metabolism or necrosis, which causes lactate peak in MRS.44 However, such acidotic 6 
change decreases the rate of proton exchange, and theoretically lessen the signal of 7 
tumors on APT image. Longo et al recently demonstrated this “Warburg effect” in the 8 
breast cancer model mice, using two-different modalities such as positron emission 9 
tomography and pH-oriented CEST image with iopamidol as an exogenous CEST 10 
contrast agent.45 APT image combined with MRS, especially chemical shift imaging 11 
including lactate peak may also offer complementary spatial information of tumor 12 
microenvironment including pH and metabolism. Recent post-processing advance, such 13 
as MT and relaxation-normalized APT, may give us additional information about 14 
intratumoral pH change.46 Second, we did not adjust for APT imaging using controls, 15 
such as contralateral normal-appearing white matter. Such adjustment might be useful 16 
for minimizing the effects of native MTRasym discussed above. However, several studies 17 
have shown that diagnostic capability did not differ between imaging with and without 18 
19 
 
such adjustment.9,11 In addition, some high-grade tumors may invade diffusely, leaving 1 
little normal-appearing white matter.47 Third, some cases with glioblastoma showed 2 
relatively high Cramer Rao Lower Bounds (CRLB) (%SD is more than 15) in NAA 3 
value. High grade gliomas often show low NAA peak due to glial cell invasion, as a 4 
result, fitting of low amount of total NAA concentration may be difficult. Although 5 
NAA with larger CRLB in cases with glioblastoma might be unreliable and less 6 
reproducible, exclusion of cases with glioblastoma were not beneficial in this study. 7 
Strength of this study was the fact that, to clarify the correlation, volume of interest was 8 
placed at the same location as the tumor on both MRS and APT imaging. To verify these 9 
correlations, a further study with direct comparison of histology obtained from 10 
stereotactic biopsy based on combined analysis using MRS and APT imaging may be 11 
warranted. 12 
In conclusion, significant correlations were observed between metabolite 13 
concentrations and ratios on MRS and APT values. MRS and APT imaging showed 14 
comparable diagnostic capability for grading brain tumors, suggesting that both MRS 15 
and APT imaging offer potential for assessing the proliferative activity of brain tumors 16 
on non-contrast MRI. 17 
  18 
20 
 
Table 1. Patient Characteristics  
















1 57 M DA 2  +ve 1.86 4.65 5.92 2.03 8.18 0.11 -0.24 3.28 
2 70 F AA 3  +ve 3.60 3.91 5.23 4.31 7.16 0.05 0.56 3.18 
3 35 M Oligo 2  -ve 1.89 3.64 4.69 0.05 2.74 0.05 0.19 3.03 
4 49 M AO 3  -ve 1.84 2.60 3.68 0.99 5.61 0.11 -0.67 3.75 
5 72 M GBM 4  +ve 8.66 3.55 4.39 3.28 7.26 0.09 -0.22 3.73 
6 71 M DA 2  -ve 0.92 2.99 4.79 -1.36 0.41 0.04 0.09 2.46 
7 44 F Oligo 2  +ve 1.31 2.21 3.54 2.46 6.20 0.06 0.13 2.49 
8 27 M GBM 4  +ve 0.79 0.56 0.70 3.55 6.61 0.07 -0.14 2.41 
21 
 
9 27 M OA 2  +ve 1.28 0.72 2.63 3.47 7.61 0.05 0.38 2.80 
10 62 F GBM 4  +ve 0.87 0.00 0.67 3.51 6.69 0.04 0.29 3.28 
11 67 M DA 2  -ve 1.81 4.13 5.20 0.23 1.72 0.04 0.08 2.51 
12 64 F GBM 4  +ve 12.83 0.20 6.23 2.72 7.75 0.07 0.42 5.09 
13 80 M DA 2  +ve 1.12 3.36 4.98 0.60 5.43 0.13 -0.81 3.00 
14 11 F AA 3  +ve 15.10 4.02 10.62 5.46 7.95 0.06 -0.22 2.66 
15 24 M Oligo 2  +ve 2.45 8.95 8.99 -0.31 5.13 0.08 0.04 3.84 
16 38 M 
GBM 
(Rec) 
4  +ve 6.00 0.17 6.25 4.91 10.58 0.14 0.52 2.23 
17 44 M 
Oligo 
(Rec) 
2  +ve 2.48 0.00 1.25 1.99 8.76 0.20 -1.22 4.61 
22 
 
18 44 F GBM 4  +ve 3.29 0.00 3.40 2.94 6.90 0.13 -0.96 3.26 
19 34 M GBM 4  +ve 1.79 1.67 2.80 0.87 7.86 0.10 0.28 3.16 
20 85 F GBM 4  +ve 2.85 3.66 4.48 -1.75 10.65 0.24 -1.27 5.10 
21 46 F Oligo 2  -ve 2.28 8.02 6.89 -2.52 3.85 0.08 -0.43 4.35 
std, standard deviation; DA, Diffuse Astrocytoma;,AA, Anaplastic Astrocytoma; OA, Oligoastrocytoma; AO, Anaplastic 
oligoastrocytoma; GBM, Glioblastoma; Oligo, Oligodendroglioma; Rec, recurrence; CE +ve represents positive contrast enhancement, 







Table 2. The correlation among parameters obtained by MRS and APT histogram 
analysis 
 


















 Cho NAA Cho/Cr NAA/Cr 
























std, standard deviation 
* p value < 0.05  
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Table 3. AUC values in ROC analysis for grading glioma with contrast enhancement on 
T1-weighted imaging, MRS, and APT imaging. 
 
Parameters Area Under the Curve 95% Confidence Interval 
Contrast Enhancement 0.65 0.47 to 0.84 
APTmean 0.82 0.62 to 1.00 
APT90 0.77 0.54 to 1.00 
Cho 0.72 0.47 to 0.97 
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Fig. 1 An 11-year-old boy diagnosed as anaplastic astrocytoma (Patient #14). The tumor 
at the corpus callosum shows tiny enhancement on CE T1-weighted image (a). VOI for 
MRS was placed on the area showing the solid portion of tumor on T2-weighted image 
(source image of APT imaging) (b). The VOI was automatically transferred to the APT 
image by in-house MATLAB script (c). On APT image, the tumor shows increased 
signal in the corpus callosum. (d) LCModel analysis shows elevation of Cho and 
decreased NAA. These findings are compatible with high-grade brain tumor. 
 
Fig. 2 A 35-year-old male diagnosed as oligodendroglioma (Patients #3). The tumor 
shows no enhancement on CE T1-weighted image (a). VOI for MRS was placed on the 
area showing the solid portion of tumor on T2-weighted image (source image of APT 
imaging) (b). On APT image, the tumor in the left frontal lobe shows similar signal 
intensity to that of the contralateral normal white matter (c). LCModel analysis shows 





Fig. 3 Receiver-operating-characteristics curve analysis for grading brain tumor with 
APT imaging, MRS and conventional MR imaging. ROC curves illustrated the 
performance of contrast enhancement, Cho, Cho/Cr, APTmean and APT90. APTmean cutoff 
of 2.72 offered the best combination of sensitivity (72.7%) and specificity (90%) in the 
characterization of high-grade gliomas, while the APT90 cut-off of 6.61 demonstrated 
the optimal combination of sensitivity (90.9%) and specificity (70%). Cho/Cr threshold 
value of 0.50 generated the best combination of sensitivity (100%) and specificity 
(93.8%) in the discrimination of high- and low-grade tumors. All the imaging 
parameters above except Cho demonstrated higher AUC values than that of contrast 
enhancement (AUC was 0.65).  
 




Fig. 1. An 11-year-old boy diagnosed as anaplastic astrocytoma (Patient #14). The tumor at the corpus 
callosum shows tiny enhancement on CE T1-weighted image (a). VOI for MRS was placed on the area 
showing the solid portion of tumor on T2-weighted image (source image of APT imaging) (b). The VOI was 
automatically transferred to the APT image by in-house MATLAB script (c). On APT image, the tumor shows 
increased signal in the corpus callosum. (d) LCModel analysis shows elevation of Cho and decreased NAA. 
These findings are compatible with high-grade brain tumor.  
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Fig. 2. A 35-year-old male diagnosed as oligodendroglioma (Patients #3). The tumor shows no 
enhancement on CE T1-weighted image (a). VOI for MRS was placed on the area showing the solid portion 
of tumor on T2-weighted image (source image of APT imaging) (b). On APT image, the tumor in the left 
frontal lobe shows similar signal intensity to that of the contralateral normal white matter (c). LCModel 
analysis shows moderate level of Cho and NAA (d). These findings are compatible with low-grade brain 
tumor.  
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Fig. 3. Receiver-operating-characteristics curve analysis for grading brain tumor with APT imaging, MRS and 
conventional MR imaging. ROC curves illustrated the performance of contrast enhancement, Cho, Cho/Cr, 
APTmean and APT90. APTmean cutoff of 2.72 offered the best combination of sensitivity (72.7%) and specificity 
(90%) in the characterization of high-grade gliomas, while the APT90 cut-off of 6.61 demonstrated the 
optimal combination of sensitivity (90.9%) and specificity (70%). Cho/Cr threshold value of 0.50 generated 
the best combination of sensitivity (100%) and specificity (93.8%) in the discrimination of high- and low-
grade tumors. All the imaging parameters above except Cho demonstrated higher AUC values than that of 
contrast enhancement (AUC was 0.65).  
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